Audited Financial Results for the Quarter and year ended 31st March, 2026 along with Statutory Auditor''s Repot thereon.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.6 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Link Pharma Chem Ltd reported a profit of Rs 7.69 Lakhs for FY26, a turnaround from a loss of Rs 102.73 Lakhs in FY25. Revenue from operations grew 7.9% to Rs 2,743.15 Lakhs from Rs 2,543.34 Lakhs. The company posted an operating profit of Rs 13.51 Lakhs before tax compared to a loss of Rs 140.25 Lakhs in the previous year. Total equity stands at Rs 1,278.92 Lakhs while total debt increased to Rs 730.41 Lakhs. The statutory auditors CNK & Associates LLP issued an unmodified opinion with no qualifications. The Board also approved re-appointment of key auditors and re-appointment of the Chairman and Managing Director (father-son duo).
The company has successfully returned to profitability after two consecutive years of losses, which is a positive signal for shareholders. However, revenue growth remains modest at under 8% and the company posted a loss in Q4, indicating uneven performance across quarters. Increased borrowings warrant monitoring.